# Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

> **NCT03937154** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 145 (actual)

## Conditions studied

- Chemotherapy-induced Thrombocytopenia

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03937154
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-26
- **Primary completion:** 2026-03-10
- **Final completion:** 2027-02-23
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03937154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03937154, "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03937154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*